Get the latest news, insights, and market updates on REGN (Regeneron Pharmaceuticals, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most profitable healthcare stocks to buy. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Q4 2025 results on January 30, with revenue coming in at $3.9 billion (+3.0% year over year), which were around 3% ahead of consensus. Profitability was even better with adjusted EPS for the quarter reaching $11.44, 7% […] Jan 31, 2026 - $REGN
Regeneron Pharmaceuticals Q4 Earnings Call Highlights
Regeneron Pharmaceuticals (NASDAQ:REGN) closed out 2025 with what executives described as another “solid quarter of commercial execution,” highlighted by continued growth in Dupixent, Libtayo, and EYLEA HD, as well as a slate of upcoming regulatory and clinical catalysts. On the company’s fourth-qua Jan 30, 2026 - $REGN
Amgen gives up on its once-prized eczema drug
The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent. Jan 30, 2026 - $REGN
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024Fourth quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 34% to $4.9 billion versus fourth quarter 2024; full year 2025 Dupixent global net sales increased 26% to $17.8 billion versus 2024Fourth quarter 2025 EYLEA HD® U.S. net sales increased 66% to $506 million and total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1. Jan 30, 2026 - $REGN
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Jan 30, 2026 - $REGN
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
Regeneron (REGN) delivered earnings and revenue surprises of +8.32% and +1.77%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Jan 30, 2026 - $REGN
Is Regeneron (REGN) Offering Value After Recent Share Price Softness?
If you are wondering whether Regeneron Pharmaceuticals is attractively priced right now, it helps to separate the headlines from what the numbers are actually saying about value. The share price recently closed at US$749.44, with returns of 10.3% over 1 year, 0.3% over 3 years, and 51.1% over 5 years. However, the year-to-date move of a 3.5% decline and shorter-term returns of a 0.8% decline over 7 days and a 3.2% decline over 30 days show that the ride has not been perfectly smooth. Recent... Jan 30, 2026 - $REGN
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple